

33rd Annual Meeting of Canadian Biomaterials Society (CBS 2017), to be held on May 24-27, 2017 at the University of Manitoba in Winnipeg.

Event Announcement

Industry/Clinician-Academic Partnership Discussion Group

(hosted by the CBS Industry/Clinician Engagement Working Group)

Friday, May 26th, 2017 from 12:15pm to 1:15pm in the EITC Atrium

Discussion Topic:

“What is required to cultivate fruitful partnerships between academics, clinicians and industry?”

The following invitees from industry and clinical practice will deliver 5-minute perspectives, followed by open discussion:

Scott M. Vickers, PhD

Engineering Program Manager, Biologics R&D, Medtronic, Nashville, TN, USA

Dr. Vickers has 10 years of experience in Biologics R&D at Medtronic leading cross-functional teams in the development of new devices and combination products to facilitate bone healing in spinal, oral-maxillofacial, and orthopedic applications. Key accomplishments have included development of four new devices in the MASTERGRAFT® family of products, with regulatory approvals in the US, Europe, Australia, China, and Japan. Other responsibilities include identification of customer needs, technical assessment of new technologies, and management of relationships and activities with academic collaborators, external suppliers, and manufacturing sites. Prior to joining Medtronic, Dr. Vickers completed doctoral studies and research at the Massachusetts Institute of Technology, with a focus on tissue engineering and regenerative medicine.



Tannin Schmidt, PhD, PEng

Associate Professor and Tier II Canada Research Chair in Biomedical Engineering – Biomaterials, University of Calgary, and co-founder of Lubris BioPharma LLC.

Dr. Schmidt's research focuses on articular cartilage and ocular surface lubrication, as well as orthopaedic and ophthalmic biomaterial/biotherapeutic development and characterization. He does contract testing and consulting with industry (e.g. Johnson & Johnson Vision Care) and is also a co-founder of Lubris BioPharma, LLC, a clinical stage biotech startup commercializing the use of recombinant human lubricin for the treatment of arthritis, dry eye, and other diseases. Novartis recently exercised an option to in-license recombinant human lubricin for ophthalmic indications worldwide (outside Europe) including the treatment of dry eye.



Dr. Richard Keijzer, MD, MSc, PhD

Pediatric Surgeon-Scientist and Associate Professor of Surgery, and Scientist of the Children's Hospital Research Institute of Manitoba, Biology of Breathing Group. Endowed Thorlakson Chair in Surgical Research for the University of Manitoba.

Dr. Keijzer's clinical interest concentrates on minimally invasive Pediatric Surgery and his research focuses on congenital anomalies in general and congenital diaphragmatic hernia and pulmonary hypoplasia in particular. He has expertise in mechanisms of normal and abnormal lung development associated with congenital diaphragmatic hernia (CDH).



Dr. Jun Wu, MD

Southwest Hospital, The Third Military Medical University, China

Dr. Wu is Director of the Institute of Burn Research, Southwest Hospital, Third Military Medical University and the Director of Chongqing Key Lab for Diseases Proteomics. He is the Elected-president of Chinese Burn Association, the President of Chinese Burn Rehabilitation Association, President of Biophysics and Regeneration Medicine Association, and a member of the standing committee of Chinese Biomaterial Society.



Questions? Would you like more information?

Contact Thomas.Willett@uwaterloo.ca